Systematic review and validation of prognostic models in liver transplantation
Matthew Jacob, James D. Lewsey, Carlos Sharpin, Alexander Gimson, Mohammed Rela, Jan H.P. van der Meulen – 22 June 2005 – A model that can accurately predict post–liver transplant mortality would be useful for clinical decision making, would help to provide patients with prognostic information, and would facilitate fair comparisons of surgical performance between transplant units.
Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation
David P. Breen, Anthony M. Marinaki, Monica Arenas, Peter C. Hayes – 22 June 2005 – Azathioprine (AZA) is a thiopurine prodrug commonly used in triple‐immunosuppressive therapy following liver transplantation. Approximately 1 in 10 patients suffers side effects in response to the drug, the most problematic being bone marrow toxicity. There is evidence that polymorphisms in the genes encoding thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPase) predict adverse drug reactions to AZA therapy.
Liver transplantation after backtable resection of giant hemangioma
Nicholas Onaca, Solly Mizrahi, Nathan Bar Nathan, Idan Burstein, Eytan Mor – 22 June 2005
Ischemia‐reperfusion of rat liver modulates hepcidin in vivo expression
John A. Goss, Philip Seu, Feng Qin Gao, Samuel Wyllie – 22 June 2005 – The recently identified acute‐phase response antimicrobial peptide hepcidin has been postulated to maintain iron homeostasis by modulating iron absorption at both the intestinal and macrophage levels. Hepcidin has also been reported to be responsible for anemia associated with chronic inflammatory diseases, and in anemia in patients with hepatic adenomas.
Liver transplantation for chronic hepatitis B with lamivudine‐resistant YMDD mutant using add‐on adefovir dipivoxil plus lamivudine
Chung Mau Lo, Chi Leung Liu, George K. Lau, See Ching Chan, Irene O. Ng, Sheung Tat Fan – 22 June 2005 – Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation. Emergence of lamivudine‐resistant YMDD mutant is common. We report the results of liver transplantation in 16 patients with pretransplantation YMDD mutants after receiving lamivudine treatment for a median of 738 days (range, 400‐1799 days).
Mycophenolate mofetil combination therapy improves long‐term outcomes after liver transplantation in patients with and without hepatitis C
Russell H. Wiesner, Jolene S. Shorr, Bettina J. Steffen, Alice H. Chu, Robert D. Gordon, John R. Lake – 22 June 2005 – To evaluate the impact of mycophenolate mofetil (MMF) on long‐term outcomes of tacrolimus and corticosteroids, we analyzed data reported to the Scientific Registry of Transplant Recipients for 11,670 adult patients (3463 with hepatitis C [HCV]) who underwent primary, single‐organ, liver transplantation between 1995 and 2001.
Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective
Norah Terrault, Bruno Roche, Didier Samuel – 22 June 2005
Critical analysis of the pediatric end‐stage liver disease scoring system: A single center experience
Benjamin L. Shneider, Ezequiel Neimark, Tamara Frankenberg, Lindsay Arnott, Frederick J. Suchy, Sukru Emre – 22 June 2005 – The Pediatric End‐Stage Liver Disease (PELD) scoring system is a new nationally utilized formula developed to provide a continuous numerical assessment of the risk of death in order to allocate livers to children for transplantation.